FP
ITCI

Foundry Partners’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Foundry Partners’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-21,405
Closed -$726K – 451
2021
Q1 		$726K Sell
21,405
-9,774
-31% -$339K 0.02% 359
2020
Q4 		$991K Buy
+31,179
New +$819K 0.04% 329

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Foundry Partners's ITCI Position: Q2 2021 in Review

Foundry Partners sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2021, closing a stake of 21,405 shares — an estimated $726K sold.

Foundry Partners first reported a position in ITCI in Q4 2020 and held it in 2 quarters. The position peaked at $991K in Q4 2020. 187 funds tracked by Wall St. Rank hold ITCI as of Q2 2021.

  • Foundry Partners reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2021 after selling out during the quarter.
  • Foundry Partners sold 21,405 Intra-Cellular Therapies Inc. shares in Q2 2021, an estimated $726K.
  • Foundry Partners first reported a position in Intra-Cellular Therapies Inc. in Q4 2020 and held it in 2 quarters.
  • Foundry Partners's Intra-Cellular Therapies Inc. position peaked at $991K in Q4 2020.
  • 187 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2021.

Based on Foundry Partners's 13F filing for Q2 2021, filed 23 Jul 2021.